How to De-risk Preclinical Lentiviral Manufacturing Ahead of IND
Lentiviral programmes often face their greatest development challenges during the transition from discovery into pre-clinical development. Approaches that perform well in early research may not provide the reproducibility, scalability, or analytical understanding required for clinical progression. This whitepaper explores the key decisions that shape successful pre-clinical development and provides practical guidance to help teams reduce risk as programmes advance toward clinical manufacturing.
What you’ll learn:
- Why the transition from discovery to pre-clinical development is a critical inflection point
- The common manufacturing and analytical challenges that emerge during early development
- How to assess whether a vector can support scalable and controlled production
- The importance of robust characterisation and process understanding for regulatory readiness
- Strategies for reducing delays and improving programme progression toward clinical manufacturing
- How early development decisions influence long-term product and process success
Why it matters:
Pre-clinical development is where lentiviral programmes move beyond biological proof-of-concept toward defined product and process understanding. Teams that establish strong manufacturing and analytical foundations early can:
- Reduce development delays
- Improve process reproducibility
- Strengthen regulatory preparedness
- Increase confidence in clinical scalability
- Accelerate progression toward clinical manufacturing
Complete the form below to access the full whitepaper!
